Eczacort30 gm

Eczacort is a medium-potency topical corticosteroid indicated for:

Established use

• Relief of the inflammatory and pruritic (itching) manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis (eczema), contact dermatitis, and other forms of dermatitis, in adults and in children as approved by formulation and age.

Guideline-supported / adjunct use

• As an adjunct measure for mild-to-moderate plaque psoriasis on the body (not scalp/face-first-line), typically for limited body surface area and short duration, alongside emollients and other standard psoriasis care.
• Seborrheic dermatitis and other corticosteroid-responsive inflammatory skin conditions, at the discretion of the prescribing physician.

Eczacort is intended for short-term, localized topical use and is not a systemic anti-inflammatory or antibiotic treatment.

Hydrocortisone Butyrate is available in topical formulations such as cream, ointment, lotion, or solution, each typically containing:

• Hydrocortisone Butyrate ... 0.1% w/w

in a suitable dermatological base. Exact strength and base may vary slightly by manufacturer/formulation; always check the product label of the dispensed pack.

Eczacort is a synthetic, mid-potency (Class 4-5 depending on formulation) topical corticosteroid ester used in dermatology for corticosteroid-responsive inflammatory skin conditions. It provides anti-inflammatory, antipruritic, and vasoconstrictive activity when applied to the skin, helping to reduce redness, swelling, and itching associated with dermatitis and eczema.

Eczacort is generally considered a mid-potency option, suitable for many body sites, but like all topical corticosteroids it requires caution with prolonged use, occlusion, or use on thin-skinned areas such as the face, groin, and axillae.

Eczacort belongs to the therapeutic class of topical corticosteroids (mid-potency), used in dermatology for corticosteroid-responsive dermatoses such as eczema, dermatitis, and, as an adjunct, mild-to-moderate psoriasis.

Hydrocortisone Butyrate diffuses across cell membranes of skin cells and binds intracellular glucocorticoid receptors. The activated receptor complex translocates to the nucleus and modulates gene transcription, inducing synthesis of lipocortins that inhibit phospholipase A2. This reduces release of arachidonic acid and downstream inflammatory mediators (prostaglandins, leukotrienes), producing anti-inflammatory and antipruritic effects. Hydrocortisone Butyrate also causes local vasoconstriction, which reduces erythema and edema at the application site, and has mild antiproliferative activity on keratinocytes.

For external (topical) use on the skin only. Wash and dry hands before application (unless the hands are the treated area). Gently and thinly spread Eczacort over the affected skin until lightly absorbed; do not rub in vigorously or apply thick layers. Avoid contact with eyes, mouth, and mucous membranes. Do not bandage, wrap, or otherwise occlude the treated area unless the prescribing physician has specifically instructed occlusive use. Not for oral, ophthalmic, or intravaginal use.

Eczacort carries a low risk of clinically significant systemic drug interactions when used topically at recommended doses over limited body surface area, because systemic absorption is normally minimal.

• Other topical or systemic corticosteroids: Concurrent use of additional corticosteroid-containing products increases the cumulative corticosteroid load and the risk of systemic effects (e.g., HPA-axis suppression); avoid combining with other potent topical steroids unless directed by a physician.
• Occlusive dressings and other agents enhancing penetration: Use with occlusive dressings, or on broken/denuded skin, can markedly increase systemic absorption of Eczacort, raising the risk of interactions with other systemically active drugs and of systemic corticosteroid effects.
• CYP3A4 inhibitors (e.g., ritonavir, itraconazole): In the presence of extensive/prolonged use leading to systemic absorption, strong CYP3A4 inhibitors could theoretically increase systemic corticosteroid exposure; this is not expected with correct, limited topical use.

Local skin reactions are most common with Eczacort; systemic effects are uncommon with correct short-term, limited-area use but risk rises with excessive quantity, duration, occlusion, or body surface area.

Common

• Burning, stinging, or itching at the application site
• Dryness or mild irritation

Less common but significant

• Skin atrophy, striae (stretch marks), and telangiectasia (visible small blood vessels) with prolonged/excessive use
• Folliculitis, acneiform eruptions, hypertrichosis, perioral dermatitis, and hypopigmentation or hyperpigmentation at the treated site
• Allergic contact dermatitis to Eczacort or formulation excipients

Rare but serious

• Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, or hyperglycemia, with excessive/prolonged use, occlusion, or use over large body surface areas, particularly in children

Pregnancy: There are no adequate, well-controlled studies of Eczacort in pregnant women. Topical corticosteroids can be systemically absorbed, and some animal studies with potent corticosteroids given systemically at high doses have shown fetal effects. Eczacort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, in the smallest effective amount for the shortest duration, and only under a physician's direction.

Lactation: It is not known whether topically applied Eczacort is excreted in human milk in clinically significant amounts. Caution is advised; avoid application to the breast/nipple area to prevent inadvertent infant ingestion, and consult a physician before use while breastfeeding.

Prolonged or widespread use

Prolonged or widespread application of Eczacort, especially under occlusion, increases the risk of local skin atrophy, striae, and telangiectasia, as well as systemic absorption leading to HPA-axis suppression, particularly in infants and young children who have a greater skin-surface-area-to-body-weight ratio.

Site restrictions

Avoid use on the face, groin, and axillae for prolonged periods unless specifically directed by the physician, as these thin-skin/intertriginous areas are more susceptible to atrophic changes and increased absorption.

Avoid occlusion

Do not use with occlusive dressings unless specifically instructed, as occlusion markedly increases systemic absorption.

Infection

If a concurrent skin infection is present, an appropriate antifungal or antibacterial agent should be used; if response is not prompt, discontinue Eczacort until the infection is controlled. See Contraindications for untreated infections.

Avoid abrupt discontinuation after prolonged use

After prolonged or extensive use, do not stop Eczacort abruptly without medical advice, as rebound flare of the underlying skin condition or, rarely, symptoms related to adrenal suppression may occur; taper or discontinue under physician guidance.

Children

Children may be more susceptible to systemic toxicity due to a larger skin-surface-to-body-mass ratio; use in children should be limited to physician-directed, minimal-area, shortest-duration therapy. See Use in Special Populations.

Overdose is unlikely with correct topical use of Eczacort, but excessive application, prolonged use, occlusion, or use over large body surface areas can lead to significant systemic corticosteroid absorption. Signs of corticosteroid excess include HPA-axis suppression and Cushingoid features (moon face, weight gain, hyperglycemia).

Eczacort is not intended for ingestion. If accidental ingestion occurs, or if signs of systemic corticosteroid toxicity develop from excessive topical use, discontinue use and seek immediate medical attention or contact a poison control center/emergency services. Do not attempt specific home treatment beyond gently washing off residual product from the skin while awaiting medical advice.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of reach of children.

Pediatric patients

Certain Eczacort formulations (e.g., lipid-based cream) are approved for short-term use in infants from 3 months of age for atopic dermatitis; other formulations/strengths are not established for use in children. Children are at greater risk of HPA-axis suppression due to a higher skin-surface-area-to-body-weight ratio, so treatment should be limited to the smallest affected area and shortest duration necessary, under physician supervision.

Elderly patients

No specific dose adjustment is established for elderly patients, but age-related skin thinning may increase susceptibility to corticosteroid-induced atrophy; use the lowest effective amount for the shortest duration.

Hepatic/renal impairment

Use with caution; reduced clearance of any systemically absorbed corticosteroid could theoretically increase risk of systemic effects. No formal dose-adjustment data are available for topical use.

Treatment with Eczacort should generally be limited to the shortest period needed to control symptoms, commonly up to 2-4 weeks depending on the condition and formulation, with reassessment if no improvement is seen. Continuous long-term use, especially on the face or in children, is discouraged due to cumulative risk of skin atrophy and HPA-axis suppression; intermittent courses under physician supervision may be used for chronic conditions.

Topical corticosteroid (mid-potency, corticosteroid ester)

Hydrocortisone Butyrate binds intracellular glucocorticoid receptors in skin cells, and the activated receptor-drug complex translocates to the nucleus to modulate transcription of anti-inflammatory and pro-inflammatory genes. This suppresses production of inflammatory mediators (prostaglandins, leukotrienes, cytokines), reduces capillary permeability and vasodilation (producing local vasoconstriction), and decreases infiltration of inflammatory cells into the skin, resulting in reduced redness, swelling, and itching in corticosteroid-responsive dermatoses.

C

Certain Eczacort formulations are approved for short-term topical treatment of atopic dermatitis in infants as young as 3 months of age, applied as a thin film once or twice daily; safety and efficacy of other formulations or longer-term use in children have not been established. Because children have a proportionally larger skin surface area relative to body weight, they are at greater risk of systemic absorption and HPA-axis suppression; treatment should use the smallest effective amount for the shortest duration, and avoid occlusive dressings, under physician supervision.